Background {#Sec1}
==========

In the early hours after heart surgery shed mediastinal blood accumulates until the postoperative bleeding stops. Shed mediastinal blood is evacuated by chest tubes positioned around the heart and lungs connected to external blood collection canisters set to suction. Chest tube clogging, however, can lead to un-evacuated shed mediastinal retained around the heart and lungs \[[@CR1], [@CR2]\]. This can contribute to the development of tamponade, hemothorax, or bloody pericardial and pleural effusions. Patients with retained blood have more complications including postoperative atrial fibrillation (POAF) and acute kidney injury (AKI) as well as utilization of more intensive care unit (ICU) resources and longer length of stay \[[@CR1], [@CR3]--[@CR6]\]. In many cases, chest tubes are milked and stripped to attempt to clear the lumens of any clogging that can be visualized at the bedside \[[@CR7]\]. However, these approaches have been shown to be ineffective and may be potentially harmful \[[@CR8]\]. Active tube clearance (ATC) of drainage catheters was developed to allow a bedside mechanism for chest tube clearance of clot in the ICU during early recovery \[[@CR9]\]. ATC has been shown to reduce interventions for retained blood as well as reduce the incidence of POAF during the index hospitalization after surgery \[[@CR5], [@CR10]--[@CR12]\]. The purpose of this study was to determine if active tube clearance (ATC) might reduce the incidence of retained blood, as well as other associated hospital resources and costs after cardiac surgery.

Materials and methods {#Sec2}
=====================

This study included 639 consecutive patients undergoing adult cardiac surgery performed by two surgeons (YB and BW) at the New England Heart and Vascular Institute, Catholic Medical Center (CMC), Manchester, NH. The study protocol was registered (NCT02145858) and was approved by the CMC Institutional Review Board (CARD2015--6). Data was collected from our prospectively collected institutional Society of Thoracic Surgeons (STS) database. Additional analysis was supplemented with administrative data using ICD and CPT codes to obtain hospital costs. Patients were divided into those consecutive adult cardiac surgery patients who received conventional chest tubes only (Phase 0, *n* = 302), an ATC training and compliance verification segment (Phase 1, *n* = 58) and a consecutive cohort treated with ATC (Phase 2, *n* = 337). Aspirin was continued preoperatively, while thienopyridines (ADP inhibitors), and warfarin were generally held 5 to 7 days before the operation and GP IIb/IIIa were withheld within 1 day of surgery. In patients with preoperative ADP inhibitors needing urgent surgery, a thromboelastogram was performed and surgery allowed when the platelet inhibition level less than 50%. β--blockade was used in all suitable cases before and after the index procedure and amiodarone was not given prophylactically.

In all groups, all CABG patients were implanted with one 24 Fr chest tube in the retrosternal position, and one 24 Fr chest tube in the pleural space, if opened. All valve and other cases were implanted with 2 retrosternal 24 Fr chest tubes, and one in the pleural space, if opened. In Phase 0, when tube clots were identified, chest tube milking was carried out on an as needed basis at the nurses' discretion. An ATC system (PleuraFlow Active Clearance Technology; ClearFlow, Inc., Anaheim, CA) was then introduced in Phase 1 and Phase 2. ATC is a chest tube clearance apparatus with a mechanism to actively keep the entire inner lumen of the chest tube clear of obstructing blood clot or fibrinous debris \[[@CR9]\]. ATC was actuated every 15 min for the first 8 h, then every 30 min for the next 16 h, and then once an hour and as needed thereafter \[[@CR5], [@CR13]\]. No data was collected while the protocol was introduced and training completed (Phase 1). Other than the use of ATC in Phase 2, there were no other differences in the size, placement location or management of chest tubes during this study. Mediastinal chest tubes were removed 24 h postoperatively or when drainage volume was less than 50 mL during the previous 8 h. Pleural chest tubes were removed 48 h postoperatively or when drainage volume was less than 200 mL during the past 24 h.

Phase 0 patients were then compared with Phase 2 for the primary endpoint of retained blood interventions after the index procedure. Retained blood is a previously described composite endpoint that encompasses any postoperative re-intervention to treat one or more of the following in the first 30 days after an initial index procedure: Re-exploration for bleeding with washout of retained blood, pleural interventions-percutaneous (thoracentesis or supplemental chest tube placed after surgery), pleural interventions-surgical (thoracotomy or thoracoscopy for hemothorax after surgery), or pericardial interventions (pericardial window or pericardiocentesis) \[[@CR1], [@CR4], [@CR5], [@CR11]\]. All patients were monitored continuous telemetry from index surgery for 3 days in CABG only patients, and through hospital discharge for all other patients. Consistent with the STS definition, POAF was defined as an episode of atrial fibrillation/flutter lasting longer than one hour and/or requiring treatment at any time between post index surgery through hospital discharge. Patients who had a documented history of atrial fibrillation/flutter prior to surgery were excluded from the POAF sub analysis. Acute Kidney Injury (AKI) was defined by KDIGO stage \[[@CR14]\]. Chest tube output was measured on an hourly basis until chest tube removal. Hospital costs were provided by the hospital's finance department. Cost were defined as total cost data for Phase 0 and Phase 2 subjects from the time of admission to the time of discharge.

Statistical analysis {#Sec3}
--------------------

Table [1](#Tab1){ref-type="table"} describes the summary statistics, standardized difference calculation, and the statistical tests used for each variable*.* The non-symmetrically distributed continuous variables tended to have long right tails, and so the analysis calculated standardized differences after log-transforming these variables. The subscripts 0 and 2 refer to Phase 0 and Phase 2 and the symbols $\documentclass[12pt]{minimal}
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                \begin{document}$$ \frac{\hat{p_2}-\hat{p_0}}{\sqrt{\left(\hat{p_2}\left(1-\hat{p_2}\right)+\hat{p_0}\left(1-\hat{p_0}\right)\right)/2}} $$\end{document}$Fisher's exact testMcNemar's test Table 2Demographic and Pre/Intra-operative Characteristics (Unmatched)Variable (mean n, %)All (*n* = 639)P0 (*n* = 302)P2(*n* = 337)*p* valueAge (years)66 ± 11.667 ± 10.265.1 ± 12.60.036Gender (male)441 (69%)205 (68%)236 (70%)0.61Weight (kg)89 ± 2088 ± 2090 ± 210.13Diabetes274 (43%)118 (39%)156 (46%)0.078Hypertension515 (81%)243 (80%)272 (81%)1Prior PCI155 (24%)70 (23%)85 (25%)0.58NYHA I329 (51%)162 (54%)167 (50%)0.3NYHA II, III or IV310 (49%)140 (46%)170 (50%)0.3Preop atrial arrhythmia131 (21%)59 (20%)72 (21%)0.62Preop-IABP50 (7.8%)25 (8.3%)25 (7.4%)0.77ADP inhibitors55 (8.6%)37 (12%)18 (5.3%)0.0027Preop Aspirin621 (97%)300 (99%)321 (95%)0.0015Preop Warfarin6 (0.94%)3 (0.99%)3 (0.89%)1GIIb/IIIa7 (1.1%)7 (2.3%)0 (0%)0.0051First Time Surgery601 (94%)284 (94%)317 (94%)1Reoperation38 (5.9%)18 (6%)20 (5.9%)1Operative Status (Elective)269 (42%)130 (43%)139 (41%)0.69Opertive Status (Non Elective)370 (58%)172 (57%)198 (59%)0.69CABG359 (56%)167 (55%)192 (57%)0.69Valve79 (12%)49 (16%)30 (8.9%)0.0056CABG + Valve78 (12%)38 (13%)40 (12%)0.81Other123 (19%)48 (16%)75 (22%)0.045CPB (yes)295 (46%)140 (46%)155 (46%)0.94Abbreviations: Coronary Artery Bypass Surgery (CABG), Cardiopulmonary Bypass (CPB), Glycoprotein GIIb/IIIa inhibitor (GIIb/IIIa), Intra Aortic Balloon Pump (IABP), New York Heart Association (NYHA), Percutaneous Cardiac Interventions (PCI)

Results {#Sec4}
=======

Unmatched patient characteristics and outcomes are presented in Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}. After propensity matching, 260 of 302 patients in Phase 0 were selected for comparison with 260 matched patients in Phase 2. The propensity matching balanced the Phase 0 and Phase 2 patients with respect to the demographic and pre/intra-operative characteristics (Table [5](#Tab5){ref-type="table"}). In Phase 2 more than 1 ATC were used in select cases resulting in an average of 1.2 ATC inserted per patient in the retrosternal position over an open pericardium. The overall incidence of retained blood in matched Phase 0 patients through the first 30 days at baseline (Phase 0) was 23% (60/260), with a 59% reduction to 9.6% (25/260) in the matched Phase 2 patients (*P* \< 0.001). (Table [6](#Tab6){ref-type="table"}) The number needed to treat for this RBS reduction was 7.4 \[95% CI 5--14.6, *p* = 0.001} The rate of percutaneous pleural interventions was similarly reduced in the analysis from 22% in Phase 0 to 8.1% (P \< 0.001) in Phase 2. Patients in Phase 2 had a reduced number of pleural interventions. (139 vs 53, *p* = 0.002). The other less common components of the retained blood composite such as re-exploration for bleeding, pericardial drainage procedures, surgical pleural drainage procedures were not significantly different between phases. Phase 2 patients had a 32.4% reduced incidence of POAF (37% in Phase 0 to 25% in Phase 2; *p* = 0.011) (Table [5](#Tab5){ref-type="table"}). The NNT for the reduction in POAF was 8.7 \[CI 4.9--43.6, *p* = −.014\] There was a reduction in KDIGO stage 1 AKI from 30 to 17% (*P* = 0.0014) and total chest tube output was significantly lower in Phase 2. (1152 ml vs 1037.50 mL, *p* = 0.02) There were no statistically significant reductions in hospital mortality, cardiac arrest, or permanent stroke. (Table [6](#Tab6){ref-type="table"}) Additionally, there was a marked reduction total ICU hours (43 \[24--79\] vs 29.75 \[24--49\], *p* \< 0.001); ICU stay \> 3 days 27% vs 12%, \< 0.001), time on the ventilator in hours (9.1 \[5--20\] vs 7.3 \[4.9--17.2\], p 0.004). (Table [7](#Tab7){ref-type="table"}) Postoperative length of stay was reduced by 1 day from 6 \[4--8\] to 5 \[4--6.25\], (*P* \< 0.001). The matched median costs (Table [8](#Tab8){ref-type="table"}) were reduced by -\$1831.45 (\[−\$3580.52; \$82.38\], *p* = 0.04) the mean costs (Table [9](#Tab9){ref-type="table"}) reduced by an average of -\$2696 (\[−\$6027.59; \$880.93\], *p* = 0.116). Table 3Postoperative Outcomes (Unmatched)Variable (mean or mean, n, %)P0 (*n* = 302)P2 (*n* = 337)*p* valueRB (composite)72 (24%)31 (9.2%)\< 0.001Re-exploration6 (2%)3 (0.89%)0.32Pleural Intervention-Percutaneous69 (23%)25 (7.4%)\< 0.001Pleural Intervention- Surgical2 (0.66%)1 (0.3%)0.6Pericardial Intervention4 (1.3%)4 (1.2%)1\# Pleural Effusion drained168590.001POAF93 (37%) (*n* = 251)67 (25%) (*n* = 270)0.0032Cardiac arrest8 (2.6%)8 (2.4%)1Postoperative blood products used72 (24%)61 (18%)0.079CTO (mL) first 24 h740 \[561.3--975\]680 \[532--910\]0.016Total CTO (mL)1136 \[834.3--1645\]1040 \[760--1430\]0.041Total CT (days)3 \[3--4\]2 \[2--2\]\< 0.001Infection (any)39 (13%)14 (4.2%)\< 0.001Surgical site deep0 (0%)0 (0%)1Surgical site superficial0 (0%)0 (0%)1Surgical site mediastinitis0 (0%)0 (0%)1Pneumonia20 (6.6%)6 (1.8%)0.0022Septicemia4 (1.3%)0 (0%)0.049UTI11 (3.6%)4 (1.2%)0.064C. Diff3 (0.99%)2 (0.59%)0.67Highest postop- creatinine1.1 \[0.905--1.4\]1 \[0.83--1.33\]\< 0.001AKI Stage 185 (28%) (*n* = 299)67 (20%) (*n* = 332)0.02AKI Stage 28 (2.7%)8 (2.4%)1AKI Stage 34 (1.3%)3 (0.9%)0.71Postop-renal dialysis7 (2.3%)2 (0.59%)0.092Stroke2 (0.66%)4 (1.2%)0.69Mortality7 (2.3%)9 (2.7%)0.81Abbreviations: Retained Blood (RB), Postoperative atrial fibrillation (POAF); Chest tube output (CTO); Chest tube (CT), Urinary Tract Infection (UTI), *Clostridium difficile* (C.Diff), Acute Kidney Injury (AKI) Table 4ICU and Hospital Length of Stay (unmatched)Variable (median or mean %)P0 (*n* = 302)P2 (*n* = 337)*p* valueICU time (Hrs.)44.5 \[24--83\]30 \[24--49\]\< 0.001ICU stay \> 3 days82 (27%)43 (13%)\< 0.001Total time on ventilator (Hrs.)8.7 \[5--19.7\]8.2 \[5.0--17.5\]0.27Ventilation \> 24 h.49 (16%)39 (12%)0.11Hospital LOS (d)8 \[5--11\]7 \[5--10\]0.017Post-op LOS (d)6 \[4--8\]5 \[4--7\]\< 0.001Abbreviations: Intensive Care Unit (ICU), Hours (Hrs), Length of Stay (LOS), Postoperative (Post-op); days (d) Table 5Demographic, Preoperative and Intraoperative Characteristics (Matched)Variable\
(mean n, %)Phase 0\
(*n* = 260)Phase 2\
(*n* = 260)*p* valueAge (years)66.7 ± 10.166 ± 11.6.4Gender (male)177 (68%)177 (68%)1Weight (kg)88 ± 2190 ± 21.33Diabetes106 (41%)107 (41%)1Hypertension209 (80%)213 (82%).73Prior PCI61 (23%)66 (25%).67NYHA Class I139 (53%)133 (51%).63NYHA Class II, III or IV121 (47%)127 (49%).63Preoperative atrial arrhythmia51 (20%)49 (19%).91Preoperative IABP19 (7.3%)22 (8.5%).74ADP inhibitors18 (6.9%)18 (6.9%)1Preoperative Aspirin258 (99%)257 (99%)1Preoperative Warfarin3 (1.2%)3 (1.2%)1GIIa/IIIa0 (0%)0 (0%)1First Time Surgery244 (94%)246 (95%).86Reoperation16 (6.2%)14 (5.4%).86Operative Status(Elective)112 (43%)117 (45%).71Operative Status(Non-elective)148 (57%)143 (55%).71CABG147 (57%)154 (59%).54Valve30 (12%)30 (12%)1CABG + valve35 (13%)32 (12%).78Other procedure48 (18%)44 (17%).7CPB (yes)114 (44%)119 (46%).69Abbreviations: Coronary Artery Bypass Surgery (CABG), Cardiopulmonary Bypass (CPB), Glycoprotein GIIb/IIIa inhibitor (GIIb/IIIa), Intra Aortic Balloon Pump (IABP), New York Heart Association (NYHA), Percutaneous Cardiac Interventions (PCI) Table 6Postoperative Outcomes (Matched)Variable (mean or mean, n, %)Phase 0 (*n* = 260)Phase 2(*n* = 260)*p* valueRetained Blood (composite)60 (23%)25 (9.6%)\<.001Re-exploration6 (2.3%)2 (0.77%).29Pleural Intervention-Percutaneous57 (22%)21 (8.1%)\<.001Pleural Intervention- Surgical2 (0.77%)0 (0%)0.25Pericardial Intervention4 (1.5%)4 (1.5%)1\# Pleural Effusions drained13953.002POAF79 (37%) (*n* = 214)55 (25%) (*n* = 216).011Cardiac arrest8 (3.1%)5 (1.9%).58Postoperative blood products used60 (23%)48 (18%).2CT output (mL) first 24 h753 \[584--975\]678 \[539--950\].038Total CT output (mL)1152 \[854--1656\]1038 \[760--1431\].020Total CT (days)3 \[3--4\]2 \[2--2\]\<.001Infection (any)37 (14%)10 (3.8%)\<.001Surgical site deep0 (0%)0 (0%)1Surgical site superficial0 (0%)0 (0%)1Surgical site mediastinitis0 (0%)0 (0%)1Pneumonia20 (7.7%)4 (1.5%).0022Septicemia4 (1.5%)0 (0%).062UTI10 (3.8%)4 (1.5%).18C. Diff3 (1.2%)1 (0.38%).62Highest postoperative creatinine1.1 \[1--1.4\]1.0 \[0.8--1.2\]\<.001AKI Stage 178 (30%) (*n* = 257)44 (17%) (*n* = 256).0014AKI Stage 27 (2.7%) (n = 257)4 (1.6%) (n = 256).55AKI Stage 33 (1.2%) (n = 257)1 (0.39% (n = 256).62Postoperative renal dialysis7 (2.7%)0 (0%).0078Stroke2 (0.77%)2 (0.77%)1Mortality7 (2.7%)7 (2.7%)1Abbreviations: Postoperative atrial fibrillation (POAF); Chest tube (CT), Urinary Tract Infection (UTI), *Clostridium difficile* (C.Diff), Acute Kidney Injury (AKI), Table 7ICU and Hospital Length of Stay (Matched)Variable (median or mean n, %)Phase 0 (*n* = 260)Phase 2 (*n* = 260)*p* valueTotal ICU time (Hrs.)43.5 \[24--79.25\]29.75 \[24--49\]\<.001ICU stay \> 3 days70 (27%)31 (12%)\<.001Total time on ventilator (Hrs.)9.1 \[5--20\]7.3 \[4.9--17.2\].004Ventilation \> 24 h44 (17%)27 (10%).037Total hospital length of stay (d)7.5 \[5--11\]7 \[5--10\].045Total post-op length of stay (d)6 \[4--8\]5 \[4--6.25\]\<.001Abbreviations: Intensive Care Unit (ICU), Hours (Hrs), Length of Stay (LOS), Postoperative (Post-op); days (d) Table 8Median Index Hospitalization Costs by Department, using Quantile Regression (Matched)DepartmentP0Costs (95% CI)P2Difference (P2-P0)*p* valueCardiology\$9.74 (7.29, 12.19)\$13.20 (10.57, 15.83)\$3.46 (−0.13, 7.05)0.0591Laboratory\$968.86 (881.95, 1055.77)\$734.63 (665.03, 804.23)-\$234.23 (− 345.58, − 122.88)\< 0.0001Other\$1112.88 (1044.25, 1181.51)\$1764.89 (1733.14, 1796.64)\$652.01 (576.39, 727.63)\< 0.0001Radiology\$378.97 (335.58, 422.36)\$264.36 (239.27, 289.45)-\$114.61 (−164.73, −64.49)\< 0.0001Step Down/Ward\$2591.52 (2426.63, 2756.41)\$2621.32 (2455.39, 2787.25)\$29.80 (− 204.13, 263.73)0.8025Respiratory\$420.71 (341.32, 500.10)\$250.22 (212.49, 287.95)-\$170.49 (− 258.39, −82.59)0.0002ICU\$2710.08 (2369.00, 3051.16)\$1782.60 (1420.70, 2144.50)-\$927.48 (− 1424.78, −430.18)0.0003Operating Room - Index\$12,514.12 (11,829.12, 13,199.12)\$12,395.89 (11,907.61, 12,884.17)-\$118.23 (− 959.44, 722.98)0.7826Blood Bank\$120.14 (71.77, 168.51)\$73.10 (51.45, 94.75)-\$47.04 (−100.04, 5.96)0.0818OR/Anesthesia\$525.61 (516.73, 534.49)\$511.53 (503.17, 519.89)-\$14.08 (−26.27, −1.89)0.0237Pharmacy\$2181.44 (2010.88, 2352.00)\$1430.57 (1325.98, 1535.16)-\$750.87 (−950.94, − 550.80)\< 0.0001Total\$25,072.80 (23,662.97, 26,482.63)\$23,241.35 (22,206.16, 24,276.54)-\$1831.45 (−3580.52, −82.38)0.0402 Table 9Mean Index Hospitalization Costs (\$) by Department, with 95% CI from bootstrapping (Matched)DepartmentCosts (95% CI)*p* valueP0P2Difference (P2-P0)Cardiology\$323.00 (177.44, 498.57)\$457.36 (202.86, 780.58)\$134.36 (− 194.43, 491.74)0.466Laboratory\$1111.94 (1021.96, 1203.00)\$900.76 (831.97, 975.97)-\$211.18 (− 316.80, −99.11)\< 0.0001Other\$1508.14 (1377.42, 1658.83)\$1875.89 (1767.38, 2005.89)\$367.75 (169.65, 550.74)\< 0.0001Radiology\$1018.82 (844.36, 1206.31)\$577.06 (473.02, 702.34)-\$441.75 (− 654.92, −234.25)\< 0.0001Step Down/Ward\$2955.18 (2724.31, 3,223.20)\$3012.16 (2685.25, 3,387.11)\$56.98 (− 346.77, 484.92)0.760Respiratory\$856.63 (678.98, 1037.94)\$569.12 (440.17, 730.86)-\$287.51 (−511.17, −46.08)0.020ICU\$4887.07 (4020.89, 5802.31)\$3919.07 (3110.13, 4956.25)-\$968.00 (− 2199.04, 365.86)0.156Operating Room\$14,024.07 (13,528.39, 14,538.16)\$13,631.57 (13,086.79, 14,125.95)-\$392.50 (− 1028.30, 309.46)0.244Blood Bank\$811.35 (616.39, 1022.17)\$571.44 (393.92, 776.12)-\$239.91 (− 510.83, 31.15)0.088OR/Anesthesia\$548.80 (536.12, 562.48)\$531.82 (521.51, 543.23)-\$16.97 (−33.86, 0.99)0.074Pharmacy\$3175.06 (2723.25, 3713.31)\$2259.84 (1858.48, 28,18.09)-\$915.22 (− 1595.18, − 196.74)0.014Total\$31,549.19 (29,149.07, 34,144.06)\$28,852.59 (26,677.52, 31,341.75)-\$2696.59 (−6027.70, 880.93)0.116

Discussion {#Sec5}
==========

Chest tubes are used routinely in the intensive care setting to clear blood and air from the mediastinal and pleural spaces after cardiac and thoracic surgery and trauma. Chest tube clogging can develop when shed blood comes in contact with the inside of drainage catheters, occurring in up to 36% of prospectively evaluated heart surgery patients \[[@CR2], [@CR15]\]. Chest tube stripping, milking and open suction have been utilized in an attempt to prevent chest tube clogging, but its safety and efficacy are not shown when reviewed in meta-analysis of randomized trials \[[@CR8]\]. In particular, a major issue for chest tube stripping and milking is the potential for the high negative pressures generated to injure the heart or great vessels, further exacerbating bleeding. Thus alternatives are needed to allow protocols to be implemented to prevent chest tube clogging. ATC was developed as a low risk alternative to these approaches \[[@CR9]\]. In preclinical studies ATC was more effective in evacuating blood, even when smaller diameter tubes were compared to larger diameter tubes \[[@CR16], [@CR17]\]. Clinically ATC is readily integrated into the operating room and ICU without disruption of the usual workflow \[[@CR13]\].

To quantify the clinical sequelae of chest tube clogging, a composite clinical endpoint of retained blood interventions was proposed in prior publications \[[@CR1], [@CR3]--[@CR5]\]. Retained blood as an endpoint is defined as any postoperative intervention to remove blood, blood clot or bloody fluid after cardiac surgery \[[@CR4]\]. This includes taking a patient back to wash out mediastinal clot or hemothorax, inserting an additional chest tube in the ICU, thoracentesis or pericardial drainage for bloody effusions. Sirch, et al., previously demonstrated a 43% relative risk reduction in retained blood in an all comers population of cardiac surgery patients treated with ATC, and Maltais, et al., reported a 59% reduction in retained blood in a mechanical assist cohort of patients \[[@CR5], [@CR11]\]. Likewise in this study, we noted a 59% relative risk reduction in retained blood in matched patients.

The primary driver of the reduction in the retained blood composite endpoint were interventions to drain pleural effusion by thoracentesis. In this series over the course of 30 days, 22% of Phase 0 patients required at least one pleural intervention which was reduced to 8.1% in patients in Phase 2. The majority of early pleural effusions are known to be bloody and inflammatory after cardiac surgery \[[@CR18], [@CR19]\]. By minimizing retained blood in the pericardium and pleural spaces there could be less of an inflammatory process driving fluid exudation from the inflamed mesothelium during recovery \[[@CR4]\]. Although there was a trend toward reduced take back for re-exploration for bleeding for washout of mediastinal clot the sample sizes was too small for statistical comparison \[[@CR20]\].

In this study, as also seen by Sirch, et al., the volume of bleeding (measured as chest tube output) was significantly less in Phase 2 patients at 24 h and in total \[[@CR5]\]. While this may seem counter intuitive, it suggest there may be an advantage of more rapidly clearing shed mediastinal blood to prevent on going microvascular bleeding from the cut surfaces in the early hours after surgery. Tissue plasminogen activator (t-PA) is known to significantly accumulate in shed mediastinal blood, which can promote on going microvascular bleeding within the postsurgical space if not promptly evacuated by chest tubes \[[@CR21]\]. Therefore perhaps having shed mediastinal blood more effectively evacuated could leave less t-PA remaining in contact with these tissues, facilitating a more rapid achievement of microvascular hemostasis in this time period.

Retained blood is recognized as an important trigger for POAF in susceptible individuals after heart surgery \[[@CR22]--[@CR24]\]. Blood not evacuated from the pericardial space coagulates, generating thrombin that recruits neutrophils which promote a localized inflammatory response on the surface of the atrium that is highly pro-oxidant and inflammatory \[[@CR6]\]. In patients who have susceptible atrial substrate this oxidative response can trigger POAF \[[@CR23]\]. In the present study, there was a 32.4% reduction in POAF. This is consistent with the studies by Sirch, where patients treated with ATC had a 30% reduction in POAF, and St. Onge, where there was a 34% reduction in POAF \[[@CR5], [@CR12]\]. This could have a significant impact on hospital resource utilization, as POAF is known to significantly increase hospital costs \[[@CR25]\].

AKI is a well-recognized complication of cardiac surgery in the postoperative period \[[@CR14]\]. In this study, patients with ATC had lower postoperative creatinine levels as well as a significant reduction in the need for postoperative dialysis. The calculated KDIGO stage I AKI rate was 30% during Phase 0, controls, dropping to 17% in Phase 2 (*P* = 0.0014). There was a trend towards a reduction in KDIGO stage II and III AKI, but the sample sizes were too small for this analysis. This study was not designed to specifically study these endpoints or the mechanism by which this may occur. However, several mechanisms can be considered such as a reduction in hypotension from tamponade or hypoxia from effusions might put less stress on the kidneys during recovery. Additionally, perhaps if there is less retained blood there is less reabsorption of oxidized products of which are known to contribute to AKI \[[@CR26]\]. AKI imposes a sizable financial burden for hospitals and thus reducing this outcome could contribute to a reduction of overall hospital costs \[[@CR27]\]. Further studies are indicated to more specifically evaluate this endpoint and the possible mechanisms of how ATC might be an additional adjunct to help minimize AKI after heart surgery.

Patients with ATC had a reduction in hospital resource utilization including a reduction in ICU hours, ICU stays of over 3 days, and reduced incidence of prolonged intubation (defined as \> 24 h). There was a statistically significant reduction in infections, primarily driven by a reduction in pneumonia and sepsis. Patients in Phase 2 had a 1 day reduced total and hospital postoperative length of stay, again, which could have significant hospital resource use implications (measured in costs, not charges) \[[@CR5], [@CR12]\]. This suggests that ATC is economically justifiable for hospitals, even after including the costs of acquiring the technology. In the United States, ATC costs approximately \$395 per unit, and in this study it was implemented as a preventative measure in all patients. Our program performs 700 cardiac cases on a yearly basis. Assuming that 700 cases a year utilizing 1.2 ATC per case, the yearly costs to implement ATC is \$331,800. A median net savings of \$1831 per patient over 700 patients would result in a net recuperation of \$1,281,700 per year for the hospital. A mean net savings of \$2696 per patient over 700 patients would result in a net recuperation of \$1,887,200 per year for the hospital. Both of these sums provide a considerable margin for cost effectiveness from a hospital purchasing perspective. This important administrative consideration is crucial in the current healthcare environment which endeavors to increase healthcare value by reducing complications and costs \[[@CR28], [@CR29]\].

There are several limitations to this study. First, data were generated from a nonrandomized, prospectively collected observational cardiac surgical database supplemented by retrospective chart reviews. These cases, however, represented a 100% census of all cardiac surgical procedures occurring during the duration of this study, which could have limited the potential for selection bias. Second, the endpoint of retained blood relies on the analysis of patients who had interventions performed, rather than by direct imaging for retained blood. This has the disadvantage of being more dependent on the subjective decision of the operating surgeon to intervene to evacuate retained blood. On the other hand, this strictly represents the experience of only two operating surgeons who have internally consistent practice patterns. Imaging may be more likely to include retained blood of uncertain clinical significance, while relying on the definition that requires specific invasive intervention for retained blood may represent a more clinically meaningful endpoint with quality improvement ramifications. Finally, although we implemented an ATC protocol for all patients undergoing cardiac surgery in our program, it is important to note that sub populations of patients such as those having CABG only, on pump vs off pump CABG, valve surgery, reoperations and more complex combined procedures have different risks and patterns of postoperative bleeding and thus may have differing clinical responses to such a clinical protocol. Further studies are needed that are statistically powered to examine these different cardiac surgery populations so that the outcomes with this approach can be better defined and protocols more specifically developed to best serve these patients.

Conclusion {#Sec6}
==========

The use of ATC is associated with a reduction in retained blood, POAF, AKI, blood loss, ICU and hospital resource utilization and median costs. This supports the concept that efforts to actively maintain chest tube patency in the ICU after heart surgery improve outcomes and are economically justified to help reduce hospital resource utilization after cardiac surgery.
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